CellaVision — Board/Management Information 2022

Jan 13, 2022

Magnus Blixt leaves his position as CFO of CellaVision AB

CellaVision's Chief Financial Officer (CFO), Magnus Blixt has informed that he will leave his position as CFO of CellaVision, to take on the position as CEO of the medical technology company Dignitana AB. Magnus will continue to support CellaVision until mid-April 2022.

"Magnus has been CFO of CellaVision for more than 8 years, including a short period as acting CEO in 2020-2021. During his time in the company, Magnus has been a vital part of CellaVision's development and success. He will be leaving CellaVision well positioned for continued growth with robust financial fundamentals in place. I would like to thank Magnus for his contributions over the years and I wish him every success with his new opportunity", says Simon Østergaard, President and CEO of CellaVision.

"My time with CellaVision has been fantastic. I am very pleased to see that the passion and entrepreneurial spirit that I encountered in 2013 remains within the organization today. It has been incredibly inspiring to see the development of this efficient and scalable business model which has delivered profitable growth over the years. With a widened product portfolio and market presence, the journey will undoubtably continue in the future," says Magnus Blixt, CFO of CellaVision.

The search for a new CFO of CellaVision will be initiated immediately and the successor will be announced in due course.

Contact

Adele Horn Corporate Communications & Investor Relations Direct: +46 (0) 464 602 604 Mobile: +46 (0) 722 065 088

About Us

CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company´s 18 local market support organizations covering more than 40 countries. In 2020, sales were SEK 471 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www. cellavision.com

This information is information that CellaVision is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-01-13 08:20 CET.

Attachments

Magnus Blixt leaves his position as CFO of CellaVision AB